Solid Tumors Market in Asia Pacific to 2019 – New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies

調査会社GBI Research社が発行したリサーチレポート(データ管理コード:GBIR403170033)
◆発行会社/調査会社:GBI Research
◆商品コード:GBIR403170033
◆発行日:2013年9月30日
◆調査対象地域:アジア太平洋
◆ページ数:111
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD7,000 ⇒換算¥770,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD10,500 ⇒換算¥1,155,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
GBI Research社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[Solid Tumors Market in Asia Pacific to 2019 – New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Solid Tumors Market in Asia Pacific to 2019 – New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Solid Tumors Market in Asia Pacific to 2019 – New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies”, which provides in-depth analysis of four key therapeutic indications within the Asia-Pacific (APAC) solid tumors market – bladder cancer, ovarian cancer, pancreatic cancer and prostate cancer – covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these four solid tumor types.

The value of the solid tumors market in the APAC region amounted to an estimated $1 billion in 2012 and is expected to register a modest Compound Annual Growth Rate (CAGR) of 12.3% to reach $2.3 billion in 2019. The key drivers for growth in this market include: new product approvals in ovarian, pancreatic and prostate cancers; expected launches from the promising ovarian and prostate cancer pipelines; and increased market penetration due to the anticipated implementation of social insurance in China. Conversely, the growth of the market in this region could face some restricting influences, including: the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; low access and penetration; and price erosion due to generic competition.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the bladder cancer, ovarian cancer, pancreatic cancer and prostate cancer in the four APAC markets of Australia, China, India and Japan. The report includes –
- Disease overview, as well as treatment algorithms and treatment usage patterns
- Market size and forecast for the APAC solid tumors market from 2012 to 2019
- Major marketed products in the APAC region for all four solid tumor types covered
- In-depth pipeline analysis for all four solid tumor types
- Key drivers and restraints that have had and are expected to have a significant impact upon the market
- Key licensing and co-development agreements in the solid tumors market

Reasons to buy

The report will enhance your decision-making capability by allowing you to –
- Align your product portfolio to the markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the solid tumors market
- Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

*** レポート目次(コンテンツ)***

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10
2 Solid Tumors Market in Asia Pacific to 2019 – Introduction 11
2.1 Introduction 11
3 Solid Tumors Market in Asia Pacific to 2019 – Therapeutic Landscape 12
3.1 Bladder Cancer 12
3.1.1 Symptoms 12
3.1.2 Etiology 12
3.1.3 Pathophysiology 12
3.1.4 Diagnosis 12
3.1.5 Classification 13
3.1.6 Epidemiology 14
3.1.7 Prognosis and Disease Staging 15
3.1.8 Treatment Options 17
3.2 Ovarian Cancer 22
3.2.1 Symptoms 22
3.2.2 Etiology 22
3.2.3 Pathophysiology 23
3.2.4 Diagnosis 23
3.2.5 Classification 25
3.2.6 Epidemiology 25
3.2.7 Prognosis and Disease Staging 26
3.2.8 Treatment Options 28
3.3 Pancreatic Cancer 31
3.3.1 Symptoms 31
3.3.2 Etiology 31
3.3.3 Pathophysiology 32
3.3.4 Diagnosis 32
3.3.5 Classification 32
3.3.6 Epidemiology 32
3.3.7 Prognosis and Disease Staging 34
3.3.8 Treatment Algorithm 36
3.4 Prostate Cancer 37
3.4.1 Symptoms 37
3.4.2 Etiology 37
3.4.3 Pathophysiology 37
3.4.4 Co-Morbidities and Complications 38
3.4.5 Diagnosis 38
3.4.6 Classification 39
3.4.7 Epidemiology 39
3.4.8 Prognosis and Disease Staging 41
3.4.9 Treatment Options 43
4 Solid Tumors Market in Asia Pacific to 2019 – Marketed Products 45
4.1 Bladder Cancer 45
4.2 Ovarian Cancer 45
4.3 Pancreatic Cancer 46
4.4 Prostate Cancer 47
4.5 Key Marketed Products 47
4.5.1 Carboplatin 47
4.5.2 Cisplatin 48
4.5.3 Gemcitabine 48
4.5.4 Paclitaxel 49
4.5.5 Doxorubicin 49
4.5.6 Avastin (bevacizumab) 50
4.5.7 Tarceva (erlotinib) 51
4.5.8 Sutent (sunitinib) 52
4.5.9 Afinitor (everolimus) 53
4.5.10 Taxotere (docetaxel) 54
4.5.11 Zytiga (abiraterone acetate) 54
4.5.12 Jevtana (cabazitaxel) 56
5 Solid Tumors Market in Asia Pacific to 2019 – Pipeline Analysis 57
5.1 Bladder Cancer Pipeline 57
5.1.1 Overall Pipeline 57
5.1.2 Pipeline Analysis by Molecule Type 58
5.1.3 Pipeline Analysis by Mechanism of Action 59
5.2 Ovarian Cancer Pipeline 60
5.2.1 Overall Pipeline 60
5.2.2 Pipeline Analysis by Molecule Type 62
5.2.3 Pipeline Analysis by Mechanism of Action 63
5.3 Pancreatic Cancer Pipeline 64
5.3.1 Overall Pipeline 64
5.3.2 Pipeline Analysis by Molecule Type 65
5.3.3 Pipeline Analysis by Mechanism of Action 66
5.4 Prostate Cancer Pipeline 67
5.4.1 Overall Pipeline 67
5.4.2 Pipeline Analysis by Molecule Type 68
5.4.3 Pipeline Analysis by Mechanism of Action 69
5.5 Promising Drug Candidates in the Pipeline 70
5.5.1 Abraxane (albumin-bound paclitaxel) 70
5.5.2 AMG 386 (trebananib) 70
5.5.3 Votrient (pazopanib) 71
5.5.4 Xtandi (enzalutamide) 72
6 Solid Tumors Market in Asia Pacific to 2019- Market Forecast 73
6.1 Asia-Pacific Market 73
6.1.1 Treatment Usage Patterns 73
6.1.2 Annual Cost of Treatment 73
6.1.3 Market Size 73
6.2 India 75
6.2.1 Treatment Usage Patterns 75
6.2.2 Annual Cost of Treatment 75
6.2.3 Market Size 75
6.3 Australia 77
6.3.1 Treatment Usage Patterns 77
6.3.2 Annual Cost of Treatment 77
6.3.3 Market Size 78
6.4 China 80
6.4.1 Treatment Usage Patterns 80
6.4.2 Annual Cost of Treatment 80
6.4.3 Market Size 80
6.5 Japan 82
6.5.1 Treatment Usage Patterns 82
6.5.2 Annual Cost of Treatment 82
6.5.3 Market Size 82
6.6 Drivers and Barriers for the Solid Tumors Market in APAC 84
6.6.1 Drivers 84
6.6.2 Barriers 84
7 Solid Tumors Market in Asia Pacific to 2019 – Deals and Strategic Consolidations 86
7.1 Deals Analysis 86
7.2 Major Co-Development Deals 87
7.2.1 ScinoPharm Taiwan and Coland Enter into Agreement to Develop Generic Oncological Drugs 88
7.2.2 Bind Biosciences Enters into Agreement with Amgen to Develop Cancer Drugs 88
7.2.3 Merck Enters into Co-Development Agreement with Endocyte for Cancer Drug 88
7.2.4 Merck Serono Enters into Co-Development Agreement with Threshold Pharma for TH-302, Pancreatic Cancer Drug 89
7.2.5 Seattle Genetics Exercises Option for Co-Development Agreement with Agensys (affiliate of Astellas) for ASG-15ME 89
7.3 Major Licensing Deals 90
7.3.1 Spectrum Pharma Amends Licensing Agreement with Allergan for Apaziquone 91
7.3.2 Chugai Pharma Enters Into Licensing Agreement with Debiopharm Group for FF284 91
7.3.3 Baxter International Enters into Licensing Agreement with Onconova Therapeutics for Rigosertib 91
7.3.4 Dyax Enters Into Licensing Agreement with Kadmon for Oncology Drug 91
7.3.5 Medigene Extends Licensing Agreement with Syncore for EndoTAG-1 92
8 Solid Tumors Market in Asia Pacific to 2019 – Appendix 93
8.1 Pipeline Drugs by Phase 93
8.1.1 Phase III 93
8.1.2 Pre-registration/NDA-filed 94
8.2 Market Forecasts to 2018 95
8.2.1 APAC 95
8.2.2 Australia 96
8.2.3 China 98
8.2.4 India 99
8.2.5 Japan 101
8.3 Market Definitions 102
8.4 Abbreviations 102
8.5 Sources 104
8.6 Research Methodology 107
8.6.1 Coverage 107
8.6.2 Secondary Research 107
8.6.3 Primary Research 108
8.6.4 Therapeutic Landscape 108
8.6.5 Geographical Landscape 110
8.6.6 Pipeline Analysis 111
8.7 Expert Panel Validation 111
8.8 Contact Us 111
8.9 Disclaimer 111

1.2 List of Figures
Figure 1: Solid Tumors Market, Asia-Pacific, Bladder Cancer, Epidemiology, 2012–2019 14
Figure 2: Solid Tumors Market, Bladder Cancer, Treatment Algorithm, Superficial and Stage I, 2013 19
Figure 3: Solid Tumors Market, Bladder Cancer, Treatment Algorithm, Stage II and III, 2013 19
Figure 4: Solid Tumors Market, Asia-Pacific, Ovarian Cancer, Epidemiology, 2012–2019 26
Figure 5: Solid Tumors Market, Ovarian Cancer, Treatment Algorithm, Stage I and II, 2013 29
Figure 6: Solid Tumors Market, Ovarian Cancer, Treatment Algorithm, Stage III and IV, 2013 30
Figure 7: Solid Tumors Market, Asia-Pacific, Pancreatic Cancer, Epidemiology, 2012–2019 33
Figure 8: Solid Tumors Market, Pancreatic Cancer, Treatment Algorithm, 2013 36
Figure 9: Solid Tumors Market, Asia-Pacific, Prostate Cancer, Epidemiology, 2012–2019 40
Figure 10: Solid Tumors Market, Prostate Cancer, Treatment Algorithm, 2013 44
Figure 11: Solid Tumors Market, Global, Avastin, Annual Sales ($m), 2006–2013e 50
Figure 12: Solid Tumors Market, Global, Tarceva, Annual Sales ($m), 2006–2013e 51
Figure 13: Solid Tumors Market, Global, Sutent, Annual Sales ($m), 2006–2013e 52
Figure 14: Solid Tumors Market, Global, Afinitor, Annual Sales ($m), 2009–2013e 53
Figure 15: Solid Tumors Market, Global, Zytiga, Annual Sales ($m), 2011–2013e 55
Figure 16: Solid Tumors Market, Global, Jevtana, Annual Sales ($m), 2010–2013e 56
Figure 17: Solid Tumors Market, Global, Bladder Cancer, Pipeline, 2013 57
Figure 18: Solid Tumors Market, Global, Bladder Cancer, Pipeline by Molecule Type, 2013 58
Figure 19: Solid Tumors Market, Global, Bladder Cancer, Pipeline by Mechanism of Action, 2013 59
Figure 20: Solid Tumors Market, Global, Ovarian Cancer, Pipeline, 2013 61
Figure 21: Solid Tumors Market, Global, Ovarian Cancer, Pipeline by Molecule Type, 2013 62
Figure 22: Solid Tumors Market, Global, Ovarian Cancer, Pipeline by Mechanism of Action, 2013 63
Figure 23: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline, 2013 64
Figure 24: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline by Molecule Type, 2013 65
Figure 25: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline by Mechanism of Action, 2013 66
Figure 26: Solid Tumors Market, Global, Prostate Cancer, Pipeline, 2013 67
Figure 27: Solid Tumors Market, Global, Prostate Cancer, Pipeline by Molecule Type, 2013 68
Figure 28: Solid Tumors Market, Global, Prostate Cancer, Pipeline by Mechanism of Action, 2013 69
Figure 29: Solid Tumors Market, Asia-Pacific, Market Size ($m), 2012–2019 74
Figure 30: Solid Tumors Market, India, Market Size ($m), 2012–2019 76
Figure 31: Solid Tumors Market, Australia, Market Size ($m), 2012–2019 79
Figure 32: Solid Tumors Market, China, Market Size ($m), 2012–2019 81
Figure 33: Solid Tumors Market, Japan, Market Size ($m), 2012–2019 83
Figure 34: Solid Tumors Market, Global, Deals, 2006–2013 86
Figure 35: Solid Tumors Market, Global, Co-development Deals, 2006–2013 87
Figure 36: Solid Tumors Market, Global, Licensing Deals, 2006-2013 90
Figure 37: GBI Research Market Forecasting Model 110

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • サリチル酸ナトリウムの世界市場
    Sodium Salicylate Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germ …
  • 照明バラストの世界市場
    Lighting Ballasts Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germ …
  • 給油カードの世界市場:種類別(ブランド系カード、ユニバーサルカード、その他)、用途別(給油、駐車、車両関連サービス、通行料金、その他)
    A fuel card refers to reloadable prepaid card that is used for making payment of expenses related to a vehicle such as fuel filling, vehicle servicing, vehicle maintenance, and others. These cards are gaining popularity owing to the benefits offered such as comprehensive reporting for the fleet of c …
  • 香港の蜂蜜・ミツバチ製品市場
    The report presents analysis of honey and bee products market in Hong Kong. Scope Brief country profile includes general information and main economic indicators and specifies business environment in Hong Kong Honey and Bee Products market is analyzed by different parameters including domestic produ …
  • 世界及び中国のシリカ(ホワイトカーボンブラック)市場2017
    The 'Global and Chinese Silica(White Carbon Black) Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Silica(White Carbon Black) industry with a focus on the Chinese market. The report provides key statistics on the market status of th …
  • 利用ベース自動車保険(UBI)の世界市場:産業動向・予測
    Global usage-based insurance market is expected to reach a CAGR of 19.1% in the forecast period of 2019 to 2026. The new market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.Market Segmentation By Package type (pay-as-you-dr …
  • 中国の消費者動向及びネット通販市場動態2014-2019
    Summary “Consumer Attitudes and Online Retail Dynamics in China, 2014-2019” provides the magnitude, growth, share, and dynamics of the online retail market in China. It is an essential tool for companies active across China's online retail value chain and for new companies considering entry into the …
  • Cap Gemini S.A.(IT/電子業界):企業概要、SWOT分析、業績
    This report is a crucial resource for industry executives and anyone looking to access key information about "Cap Gemini S.A." The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follo …
  • RNL BIO Co., Ltd. (003190):企業財務及びSWOT分析(医療業界)
    Summary This comprehensive SWOT profile of RNL BIO Co., Ltd. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potentia …
  • 世界及び中国のマグネットセパレーター市場2017
    The 'Global and Chinese Magnetic Separator Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Magnetic Separator industry with a focus on the Chinese market. The report provides key statistics on the market status of the Magnetic Separ …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GBIR403170033 )"Solid Tumors Market in Asia Pacific to 2019 – New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies" はGBI Research社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。